secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRUKER CORP (BRKR)
CIK:        0001109354
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-051559
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion
--------------------------------------------------------------------------------

- Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.
- ELITech FY2023 revenue ~€150M with >80% consumables; systems include InGenius and BeGenius MDx platforms.
- Remainder 2024 expected ELITech revenue ~$100M within Bruker, non-GAAP EBIT margins >20%.
- Non-GAAP EPS accretion of $0.08-$0.10 for FY 2024 after acquisition financing costs.
- ELITech to become Bruker Molecular Diagnostics within Microbiology & Infection Diagnostics division.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/0000950170-24-051559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/brkr-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer